Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global cholera vaccines market size reached US$ 4.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 9.2 Million by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.

Cholera is an intestinal disease caused by bacterial infections that spread through contaminated food and water. It leads to severe diarrhea, dehydration, abdominal pain, fever, rapid heart rate, loss of skin elasticity, low blood pressure, muscle cramps, and dry mucous membranes, such as the inside of the mouth, throat, nose, and eyelids. It is presently a global threat to public health, which can be prevented through the vaccine. The cholera vaccine exposes a small dose of live cholera bacteria in the body that helps develop immunity against the disease. It can be given orally or injected intradermally or intramuscularly in the body.

Cholera Vaccines Market Trends:
The growing prevalence of cholera on account of poor hygiene and sanitation represents one of the major factors driving the market. In addition, there is a rise in the use of contaminated water for agriculture and olericulture across the globe. This, along with the increasing consumption of street and fast food due to the hectic lifestyles of individuals, is propelling the growth of the market. Moreover, there is a considerable rise in water pollution on account of sewage and factory wastes getting discharged into lakes and rivers. As a result, people are consuming contaminated seafood worldwide, which, in turn, is resulting in the spread of cholera. Additionally, rising awareness about cholera through initiatives of non-governmental organizations (NGOs), along with numerous immunization programs introduced by governments of several countries to reduce vaccine-preventable diseases, is positively influencing the market. Furthermore, key market players are extensively investing in research and development (R&D) activities to provide more efficient and cost-effective cholera vaccines, which is projected to propel the growth of the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cholera vaccines market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on vaccine type, product and end user.

Breakup by Vaccine Type:

Whole Cell V. Cholerae O1 with Recombinant B-Subunit
Killed Oral O1 and O139

Breakup by Product:

Dukoral
Shanchol
Vaxchora
Euvichol and Euvichol-Plus
Others

Breakup by End User:

Hospitals and Clinics
Research and Academic Laboratories
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.), Emergent BioSolutions Inc., Eubiologics Co. Ltd., Johnson & Johnson, Merck & Co. Inc, Pfizer Inc., PharmaChoice Canada Inc, Sanofi S.A., Takeda Pharmaceutical Company Limited and Valneva SE.

Key Questions Answered in This Report:
How has the global cholera vaccines market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cholera vaccines market?
What are the key regional markets?
What is the breakup of the market based on the vaccine type?
What is the breakup of the market based on the product?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cholera vaccines market and who are the key players?
What is the degree of competition in the industry?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
  2.3.1 Primary Sources
  2.3.2 Secondary Sources
2.4 Market Estimation
  2.4.1 Bottom-Up Approach
  2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Cholera Vaccines Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Vaccine Type
6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
  6.1.1 Market Trends
  6.1.2 Market Forecast
6.2 Killed Oral O1 and O139
  6.2.1 Market Trends
  6.2.2 Market Forecast
7 Market Breakup by Product
7.1 Dukoral
  7.1.1 Market Trends
  7.1.2 Market Forecast
7.2 Shanchol
  7.2.1 Market Trends
  7.2.2 Market Forecast
7.3 Vaxchora
  7.3.1 Market Trends
  7.3.2 Market Forecast
7.4 Euvichol and Euvichol-Plus
  7.4.1 Market Trends
  7.4.2 Market Forecast
7.5 Others
  7.5.1 Market Trends
  7.5.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals and Clinics
  8.1.1 Market Trends
  8.1.2 Market Forecast
8.2 Research and Academic Laboratories
  8.2.1 Market Trends
  8.2.2 Market Forecast
8.3 Others
  8.3.1 Market Trends
  8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
  9.1.1 United States
   9.1.1.1 Market Trends
   9.1.1.2 Market Forecast
  9.1.2 Canada
   9.1.2.1 Market Trends
   9.1.2.2 Market Forecast
9.2 Asia-Pacific
  9.2.1 China
   9.2.1.1 Market Trends
   9.2.1.2 Market Forecast
  9.2.2 Japan
   9.2.2.1 Market Trends
   9.2.2.2 Market Forecast
  9.2.3 India
   9.2.3.1 Market Trends
   9.2.3.2 Market Forecast
  9.2.4 South Korea
   9.2.4.1 Market Trends
   9.2.4.2 Market Forecast
  9.2.5 Australia
   9.2.5.1 Market Trends
   9.2.5.2 Market Forecast
  9.2.6 Indonesia
   9.2.6.1 Market Trends
   9.2.6.2 Market Forecast
  9.2.7 Others
   9.2.7.1 Market Trends
   9.2.7.2 Market Forecast
9.3 Europe
  9.3.1 Germany
   9.3.1.1 Market Trends
   9.3.1.2 Market Forecast
  9.3.2 France
   9.3.2.1 Market Trends
   9.3.2.2 Market Forecast
  9.3.3 United Kingdom
   9.3.3.1 Market Trends
   9.3.3.2 Market Forecast
  9.3.4 Italy
   9.3.4.1 Market Trends
   9.3.4.2 Market Forecast
  9.3.5 Spain
   9.3.5.1 Market Trends
   9.3.5.2 Market Forecast
  9.3.6 Russia
   9.3.6.1 Market Trends
   9.3.6.2 Market Forecast
  9.3.7 Others
   9.3.7.1 Market Trends
   9.3.7.2 Market Forecast
9.4 Latin America
  9.4.1 Brazil
   9.4.1.1 Market Trends
   9.4.1.2 Market Forecast
  9.4.2 Mexico
   9.4.2.1 Market Trends
   9.4.2.2 Market Forecast
  9.4.3 Others
   9.4.3.1 Market Trends
   9.4.3.2 Market Forecast
9.5 Middle East and Africa
  9.5.1 Market Trends
  9.5.2 Market Breakup by Country
  9.5.3 Market Forecast
10  SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11  Value Chain Analysis
12  Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13  Price Analysis
14  Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
  14.3.1 Astellas Pharma Inc.
   14.3.1.1 Company Overview
   14.3.1.2 Product Portfolio
   14.3.1.3 Financials
   14.3.1.4 SWOT Analysis
  14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
   14.3.2.1 Company Overview
   14.3.2.2 Product Portfolio
   14.3.2.3 Financials
   14.3.2.4 SWOT Analysis
  14.3.3 Emergent BioSolutions Inc.
   14.3.3.1 Company Overview
   14.3.3.2 Product Portfolio
   14.3.3.3 Financials
   14.3.3.4 SWOT Analysis
  14.3.4 Eubiologics Co. Ltd.
   14.3.4.1 Company Overview
   14.3.4.2 Product Portfolio
   14.3.4.3 Financials
  14.3.5 Johnson & Johnson
   14.3.5.1 Company Overview
   14.3.5.2 Product Portfolio
   14.3.5.3 Financials
   14.3.5.4 SWOT Analysis
  14.3.6 Merck & Co. Inc
   14.3.6.1 Company Overview
   14.3.6.2 Product Portfolio
   14.3.6.3 Financials
   14.3.6.4 SWOT Analysis
  14.3.7 Pfizer Inc.
   14.3.7.1 Company Overview
   14.3.7.2 Product Portfolio
   14.3.7.3 Financials
   14.3.7.4 SWOT Analysis
  14.3.8 PharmaChoice Canada Inc
   14.3.8.1 Company Overview
   14.3.8.2 Product Portfolio
  14.3.9 Sanofi S.A.
   14.3.9.1 Company Overview
   14.3.9.2 Product Portfolio
   14.3.9.3 Financials
   14.3.9.4 SWOT Analysis
  14.3.10 Takeda Pharmaceutical Company Limited.
   14.3.10.1 Company Overview
   14.3.10.2 Product Portfolio
   14.3.10.3 Financials
   14.3.10.4 SWOT Analysis
  14.3.11 Valneva SE
   14.3.11.1 Company Overview
   14.3.11.2 Product Portfolio
   14.3.11.3 Financials

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings